Show simple item record

dc.contributor.authorSadeghi-Hokmabadi, E
dc.contributor.authorFarhoudi, M
dc.contributor.authorTaheraghdam, A
dc.contributor.authorHashemilar, M
dc.contributor.authorSavadi-Osguei, D
dc.contributor.authorRikhtegar, R
dc.contributor.authorMehrvar, K
dc.contributor.authorSharifipour, E
dc.contributor.authorYouhanaee, P
dc.contributor.authorMirnour, R
dc.date.accessioned2018-08-26T07:40:56Z
dc.date.available2018-08-26T07:40:56Z
dc.date.issued2016
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/47322
dc.description.abstractBackground: In developing countries, intravenous thrombolysis (IVT) is available at a limited number of centers. This study aimed to assess the feasibility and safety of IVT at Tabriz Imam Reza Hospital. Methods: In a prospective study, over a 55-month period, any patient at the hospital for whom stroke code had been activated was enrolled in the study. Data on demographic characteristics, stroke risk factors, admission blood pressure, blood tests, findings of brain computed tomography (CT) scans, time of symtom onset, time of arrival to the emergency department, time of stroke code activation, time of CT scan examination, and the time of recombinant tissue plasminogen activator administration were recorded. National Institutes of Health Stroke Scale assessments were performed before IVT bolus, at 36 hours, at either 7 days or discharge (which ever one was earlier), and at 3-month follow-up. Brain CT scans were done for all patients before and 24 hours after the treatment. Results: Stroke code was activated for 407 patients and IVT was done in 168 patients. The rate of functional independence (modified Rankin Scale [mRS] 0-1) at 3 months was 39.2% (62/158). The mortality rate at day 7 was 6% (10/168). Hemorrhagic transformation was noted in 16 patients (9.5%). Symptomatic intracranial hemorrhage occurred in 5 (3%), all of which were fatal. One case of severe urinary bleeding and one other fatal case of severe angioedema were observed. Conclusion: During the first 4-5 years of administration of IVT in the hospital, it was found to be feasible and safe, but to increase the efficacy, poststroke care should be more organized and a stroke center should be established.
dc.language.isoEnglish
dc.relation.ispartofINTERNATIONAL JOURNAL OF GENERAL MEDICINE
dc.subjectstroke
dc.subjectdeveloping countries
dc.subjectthrombolytic therapy
dc.subjectcode team
dc.subjectrtPA
dc.subjectfunctional independence
dc.titleIntravenous recombinant tissue plasminogen activator for acute ischemic stroke: a feasibility and safety study
dc.typeArticle
dc.citation.volume9
dc.citation.spage361
dc.citation.epage367
dc.citation.indexWeb of science
dc.identifier.DOIhttps://doi.org/10.2147/IJGM.S112430


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record